-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Shanghai's biopharmaceutical industry can be described as a series of good news
.
On January 6, five new cities in Shanghai, Jiading, Songjiang, Qingpu, Fengxian and Nanhui, entered a new stage, and 40 major projects with a total investment of 132.
82 billion yuan were started, including the Desano AIDS drug development project and many other projects.
Biomedical projects
.
The implementation of these projects will mean that the new city will push forward the "turnover"
.
Recently, "2021 Shanghai Biopharmaceutical Industry Inventory" was newly released.
From the data, it can be seen that the innovation heat of Shanghai's biopharmaceutical industry in 2021 is high
.
In 2021, the total target management scale of Shanghai Biomedical Fund will reach 50 billion yuan; the first clinical trial accelerator Hi-Clip will be launched to connect the needs and resources of enterprises and hospitals to improve the quality and efficiency of the integration of production and medicine.
It is expected that the average start-up time of clinical trials will be reduced from 6-13 months were shortened to 3-5 months; capital was active, and Shanghai Biomedical Fund realized 23 investments, focusing on key areas in line with Shanghai's biomedical industry development strategy; Shanghai biomedical enterprises had a total of more than 190 financing events Among them, innovative drug research and development and new medical technologies are highly sought after; in 2021, the number of biopharmaceutical companies listed will reach 10, ranking first in the country
.
With the support of a series of favorable policies and capital, the "answer sheet" handed over by the Shanghai biopharmaceutical industry in 2021 is very eye-catching, and the "birth rate" of new drugs has reached a new high
.
In 2021, a total of 8 Class 1 domestic innovative drugs have been approved in Shanghai, far exceeding the total number of approvals in the previous two years, including fumetinib mesylate, contezolid tablets, and piamprilumab, etc.
There are two domestic CAR-T products that have been launched, namely Achilles injection under Fosun Kite and Ruiki Orenza injection under WuXi Junuo
.
Among the innovative blood cancer drugs, the launch of these two products has opened the prelude to domestic CAR-T therapy
.
Among them, Fosun Kite's akirenxe injection was approved for marketing through priority review and approval in June 2021.
This drug is the first cell therapy product approved for marketing in China.
It is used to treat second-line or above systemic patients.
Adult patients with post-treatment relapsed or refractory large B-cell lymphoma (including diffuse large B-cell lymphoma unspecified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and transformed follicular lymphoma) diffuse large B-cell lymphoma)
.
The launch of this product provides a new treatment option for adult patients with relapsed or refractory large B-cell lymphoma who have received second-line or above systemic therapy
.
Ruiki Orenza Injection is an autologous CAR-T cell immunotherapy product targeting CD19 independently developed by WuXi Junuo on the basis of Junuo Medical's CAR-T cell technology platform
.
The product was approved in September 2021 for the treatment of relapsed or refractory large B-cell lymphoma (r/r LBCL) in adult patients after second-line or above systemic therapy, becoming the first approved Class 1 biologic in China The CAR-T product of the product is also a CAR-T cell immunotherapy product that has simultaneously obtained three honors in China, including the "Major New Drug Creation" special project, the priority review qualification for new drug marketing applications, and the breakthrough treatment drug designation
.
The 14th Five-Year Plan for the Development of Strategic Emerging Industries and Leading Industries in Shanghai has clearly positioned biomedicine as a strategic emerging industry in Shanghai
.
Strive to basically build a biomedical industry innovation highland with international influence by 2025
.
According to the plan, Shanghai will center on the core area of Zhangjiang biomedical innovation leading, the Lingang new area precision medicine pilot demonstration area, the Oriental Beauty Valley life and health integration development area, the Gold Coast modern pharmaceutical green bearing area, and the North Shanghai biomedical high-end area.
Relying on the manufacturing agglomeration area and the South Hongqiao Smart Medical Innovation Pilot Zone, the brand effect of the city-level characteristic park will be brought into play to jointly build a "1+5+X" biopharmaceutical industry spatial layout
.
.
On January 6, five new cities in Shanghai, Jiading, Songjiang, Qingpu, Fengxian and Nanhui, entered a new stage, and 40 major projects with a total investment of 132.
82 billion yuan were started, including the Desano AIDS drug development project and many other projects.
Biomedical projects
.
The implementation of these projects will mean that the new city will push forward the "turnover"
.
Recently, "2021 Shanghai Biopharmaceutical Industry Inventory" was newly released.
From the data, it can be seen that the innovation heat of Shanghai's biopharmaceutical industry in 2021 is high
.
In 2021, the total target management scale of Shanghai Biomedical Fund will reach 50 billion yuan; the first clinical trial accelerator Hi-Clip will be launched to connect the needs and resources of enterprises and hospitals to improve the quality and efficiency of the integration of production and medicine.
It is expected that the average start-up time of clinical trials will be reduced from 6-13 months were shortened to 3-5 months; capital was active, and Shanghai Biomedical Fund realized 23 investments, focusing on key areas in line with Shanghai's biomedical industry development strategy; Shanghai biomedical enterprises had a total of more than 190 financing events Among them, innovative drug research and development and new medical technologies are highly sought after; in 2021, the number of biopharmaceutical companies listed will reach 10, ranking first in the country
.
With the support of a series of favorable policies and capital, the "answer sheet" handed over by the Shanghai biopharmaceutical industry in 2021 is very eye-catching, and the "birth rate" of new drugs has reached a new high
.
In 2021, a total of 8 Class 1 domestic innovative drugs have been approved in Shanghai, far exceeding the total number of approvals in the previous two years, including fumetinib mesylate, contezolid tablets, and piamprilumab, etc.
There are two domestic CAR-T products that have been launched, namely Achilles injection under Fosun Kite and Ruiki Orenza injection under WuXi Junuo
.
Among the innovative blood cancer drugs, the launch of these two products has opened the prelude to domestic CAR-T therapy
.
Among them, Fosun Kite's akirenxe injection was approved for marketing through priority review and approval in June 2021.
This drug is the first cell therapy product approved for marketing in China.
It is used to treat second-line or above systemic patients.
Adult patients with post-treatment relapsed or refractory large B-cell lymphoma (including diffuse large B-cell lymphoma unspecified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and transformed follicular lymphoma) diffuse large B-cell lymphoma)
.
The launch of this product provides a new treatment option for adult patients with relapsed or refractory large B-cell lymphoma who have received second-line or above systemic therapy
.
Ruiki Orenza Injection is an autologous CAR-T cell immunotherapy product targeting CD19 independently developed by WuXi Junuo on the basis of Junuo Medical's CAR-T cell technology platform
.
The product was approved in September 2021 for the treatment of relapsed or refractory large B-cell lymphoma (r/r LBCL) in adult patients after second-line or above systemic therapy, becoming the first approved Class 1 biologic in China The CAR-T product of the product is also a CAR-T cell immunotherapy product that has simultaneously obtained three honors in China, including the "Major New Drug Creation" special project, the priority review qualification for new drug marketing applications, and the breakthrough treatment drug designation
.
The 14th Five-Year Plan for the Development of Strategic Emerging Industries and Leading Industries in Shanghai has clearly positioned biomedicine as a strategic emerging industry in Shanghai
.
Strive to basically build a biomedical industry innovation highland with international influence by 2025
.
According to the plan, Shanghai will center on the core area of Zhangjiang biomedical innovation leading, the Lingang new area precision medicine pilot demonstration area, the Oriental Beauty Valley life and health integration development area, the Gold Coast modern pharmaceutical green bearing area, and the North Shanghai biomedical high-end area.
Relying on the manufacturing agglomeration area and the South Hongqiao Smart Medical Innovation Pilot Zone, the brand effect of the city-level characteristic park will be brought into play to jointly build a "1+5+X" biopharmaceutical industry spatial layout
.
